Brazilian Journal of Pharmaceutical Sciences
Brief Background
|
The Brazilian Journal of Pharmaceutical Sciences is published continuously by the School of Pharmaceutical Sciences of the University of São Paulo and covers the most recent advances in the field of Pharmaceutical Sciences and correlated areas. The Brazilian Journal of Pharmaceutical Sciences has its origin in 1939 with the publication of the "Anais de Farmácia e Odontologia da USP". In 1963, the Journal name changed to "Revista da Faculdade de Farmácia e Bioquímica da Universidade de São Paulo" and in 1970 the Journal was renamed again as "Revista de Farmácia e Bioquímica da Universidade de São Paulo". In 1999, the Journal was totally remodeled and renamed Revista Brazileira de Ciências Farmacêuticas/Brazilian Journal of Pharmaceutical Sciences. From 2009 on, celebrating 70 years of publishing, a new era started. The Journal adopted exclusively the English denomination and at present accepts only papers in English. In addition, in 2019 it moved to a continuous publishing mode. All these changes aimed at increasing the national and international visibility of the Brazilian Journal of Pharmaceutical Sciences towards consolidating it as one of the main journals in Pharmaceutical Sciences. The abbreviation is Braz. J. Pharm. Sci., which should be used in bibliographies, footnotes and bibliographical references and strips. |
Open Access
|
This journal follows the Open Access model, providing unrestricted virtual access (including financial restrictions) to all scientific texts published by the journal. Open Access is the condition where the copyright holder of a scholarly work grants usage rights to others using an open license (Creative Commons Attribution - CC-BY 4.0) allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose. |
Open Science Compliance
|
The Brazilian Journal of Pharmaceutical Sciences is open access. The journal adopts a series of practices, such as the open access policy and the code of good practice for editors. In addition, it requires the precise indication of the role of each author in articles with multiple authorship and encourages the sharing of analysis data sets, instruments, statistical analysis and additional materials made available in open online repositories such as Zenodo, Figshare, OSF, NCBI, Mendeley Data and SciELO Data if they cannot be published in the paper itself. This information must be indicated in the manuscript. The journal encourages the publication of preprint articles on public platforms, such as Preprints, SciELO Preprints and EmeRI, so that, where appropriate, they can be discussed openly before being published. Also, in line with open science practices, the journal offers authors and reviewers the option of opening up the peer review process, with or without identifying their names. |
Ethics in Publication
|
The Brazilian Journal of Pharmaceutical Sciences is committed to ethics and quality in publishing. The Journal conforms to the standards of ethical behavior expected of all parties involved: authors, editors, and reviewers in publishing in the journal. Submissions must assure precision of data, authorship, and transparency regarding conflict of interests. Research integrity is a priority and any misconduct including plagiarism will be taken seriously. This Journal follows the Principles of Transparency and Best Practice in Scholarly Publishing according to the Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishing Association (OASPA), and the World Association of Medical Editors (WAME), available at https://doi.org/10.24318/cope.2019.1.12 |
Focus and Scope
|
The Brazilian Journal of Pharmaceutical Sciences publishes manuscripts that significantly contribute to knowledge in all areas of Pharmaceutical Sciences including:
|
Digital Preservation
|
This journal follows the standards defined in the Digital Preservation Policy program of the SciELO Program and all articles published have an attributed DOI number. |
Indexing sources
|
The Journal is indexed and recognized by several prestigious databases and systems, which underscores its credibility and reach within the scientific community. Here is a summary of the indexing and classification details: |
Impact Factor
|
Brazilian Journal of Pharmaceutical Sciences stands at 0.6 for the year of 2023 according to the Journal Citation Reports (ClarivateTM). |
Bibliographic Journal Information
|
Editorial Policy
|
Preprints The Brazilian Journal of Pharmaceutical Sciences recognizes the importance of new scientific mediums and enables readers and researchers to have faster access to recent research findings prior to its publication. Therefore, the journal welcomes manuscripts that have been deposited on non-commercial preprint servers. A preprint is a preliminary version of a scientific work that is publicly shared in online repositories before undergoing peer review and eventual publication in a scientific journal. It is a way to accelerate the process of scientific communication, enabling researchers to promptly share their findings with the academic community. Preprints can be found in public repositories such as SciELO Preprints These repositories, maintained by non-profit organizations, provide free access to the public for reading and downloading purposes. To ensure transparency and integrity in handling preprints submitted to the Brazilian Journal of Pharmaceutical Sciences, authors must provide the following information: Preprint Identification: Title, authors, repository where it was published, publication date and DOI. Conflicts of Interest: Authors should disclose any conflicts of interest related to the preprint, such as funding from a company or institution with an interest in the work. Peer Review Process Manuscripts submitted to the Brazilian Journal of Pharmaceutical Sciences must conform to the journal's scope, undergo an initial plagiarism check by the author, and be accompanied by a plagiarism report certificate. Submissions are evaluated and, if compliant, reviewed by at least two anonymous reviewers that will evaluate the manuscript regarding novelty, scientific importance, organization, clarity, conciseness, analytical and critical skills, and adequate references. Based on these opinions, the Associate Editor makes a preliminary recommendation and the Editor-in-Chief makes the final decision on the manuscript, which can be accepted, rejected, or returned for revisions. This decision is communicated to the authors and, if revisions are needed, they must submit a revised manuscript within 30 days. The authors must justify to the Editor in case additional time is needed to prepare the revised version. The revised text must be typed in black, highlighted in yellow and be accompanied by a rebuttal letter discussing each point raised by the reviewers in a point-by-point manner. The rebuttal letter should also indicate the page and line number where each revision has been made. Revised manuscripts are reassessed, and the final decision on acceptance, rejection, or further revisions is based on this review and the editors' assessment. In line with open science principles, starting in 2024, accepted articles will be published along with the name of the editor responsible for handling and accepting the study. Editorial Process All manuscripts undergo an initial evaluation to check for the presence of all required attachments as well as the correct text format. If the authors fail to follow all submission instructions more than twice, the manuscript will be preliminarily rejected. If the manuscript meets these initial criteria, it is then reviewed by the Editor-in-Chief to assess the quality of the content and alignment with the Journal’s scope and basic policies. Following this, the manuscript is addressed to an appropriate Associate Editor and, if considered adequate, subjected to a single-blind peer review process. Based on the feedback from this review, the Editor-in-Chief decides whether the manuscript should be accepted, revised (requiring major or minor revisions), or rejected. Open Data In line with the principles of Open Science, the Brazilian Journal of Pharmaceutical Sciences encourages the sharing of data, codes, methods, and other materials used in and resulting from the research published in the Journal in the SciELO Data repository. This includes all forms of data that support the research findings, such as raw and processed data, audio and video files, code, software, algorithms, protocols, and methods. This practice is encouraged to facilitate data verification and reuse, thereby increasing the credibility and impact of the research published. Fees There are no charges for articles submission, evaluation and publication. Ethics and Misconduct Policy, Errata, and Retraction The Brazilian Journal of Pharmaceutical Sciences adheres to the publication ethics principles outlined in the Committee on Publication Ethics (COPE) code of conduct. The Editorial Body will assess and address ethical issues and/or issues that may harm the Journal's reputation. In cases of misconduct, the Journal will apply the retraction policy in accordance with the Best Practice Guide proposed by SciELO. The registration and publication of errata will follow the recommendations proposed by SciELO. Policy on Conflict of Interest We understand that transparency about competing interests is essential for the best editorial decisions and the trust of our readers. Therefore, authors, reviewers and editors must declare any potential sources of conflicts of interest. A conflict of interest or competing interest is any financial, personal, religious, political, or other affiliations or relationships that may influence or could be perceived to influence the objectivity and integrity of an author, reviewer, or editor. This includes, but is not limited to, funding from entities that could gain or lose financially from the publication, current or future employment at such organizations, personal interests like stocks ownership in related companies, and patents related to the manuscript’s content. Non-financial interests include close personal relationships, academic ties, political affiliations, or deep personal or religious beliefs. For Authors:
For Reviewers and Editors:
Important Considerations:
Example statements "Competing Interests: The authors declare no competing financial interests." "Competing Interests: Dr. Alex Brown's work has been funded by the NIH. He is a member of the scientific advisory board of Biotech Enterprise and owns stock in the company. He has also consulted for PharmaCorp and received compensation. Dr. Sarah Johnson and Dr. Mark Lee declare no potential competing interests." Adoption of similarity software Plagiarism check process is structured in two distinct stages to ensure the integrity and originality of submissions. As a first step, authors must provide a certificate of similarity/plagiarism check using any freely available online software, mentioning the program used for similarity check. The BJPS considers up to 25% of similarity acceptable (providing the correct references were cited) and up to 5% of similarity to the same reference. We also recommend the authors to avoid similarity in the Results and Discussion section. This step places the initial responsibility on the authors to ensure their work is free of plagiarism before formal review. The Editorial Team will conduct an additional plagiarism check using the iThenticate system to uphold the highest standards of scholarly publishing and maintain the integrity of the Journal's content. This two-step approach ensures that both authors and the Journal contribute to maintaining academic honesty and originality in published work. Plagiarism Plagiarism occurs when an author presents someone else's work and or ideas as their own. Duplicate publication or self-plagiarism involves reusing significant parts of one’s own published work without proper citation. This includes publishing the same paper in multiple journals or slightly modifying a previous paper by adding small new data segments. Plagiarism is evident when large sections of text are copied. Minor instances might occur without dishonest intent, such as reusing parts of an introduction from a previous paper. Each case of plagiarism is assessed by journal editors on its merits. If plagiarism is detected post-publication, a preliminary investigation follows, potentially leading to contacting the author's institute and possibly retracting the paper. Data falsification involves altering research data to mislead, such as manipulating images or omitting inconvenient results. Fabrication includes inventing data or results. Both practices severely damage the credibility of scientific research. Regarding image integrity, the manipulation for clarity is permitted but must be correctly disclosed and represent the original data. Detailed guidelines are available at the “PREPARING YOUR MANUSCRIPT” topic. Adoption of software using Artificial Intelligence resources Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement in the core manuscript file, just before the References list. This should be included in a new section titled ‘Declaration of Generative AI and AI Assisted Technologies in the Writing Process’. The use of basic tools for grammar, spelling, and reference checks does not require a declaration. If no such technologies were used, a statement should be included. Suggested Statement Model: "During the preparation of this work, the author(s) utilized [NAME OF TOOL/SERVICE] to [SPECIFIC PURPOSE]. The author(s) subsequently reviewed and modified the content as necessary and assume(s) full responsibility for the content of the publication." Or: “No tools were utilized during the preparation of this work.” See the Guide to the Use of Artificial Intelligence Tools and Resources in Research Communication on SciELO. Gender and Sex Issues The editorial team of the Brazilian Journal of Pharmaceutical Sciences, as well as the authors who publish in the journal, must always observe the guidelines on (Sex and Gender Equity in Research – SAGER). The SAGER comprises a set of guidelines regarding sex and gender information in study design, data analysis, and results interpretation. Additionally, the Brazilian Journal of Pharmaceutical Sciences observes the policy of gender equity in the editorial board composition. Ethics Committee When reporting results on humans and/or animals, the authors must present a statement of approval from the institution's ethics committee responsible for approving the research. Copyright Authors who publish in the Brazilian Journal of Pharmaceutical Sciences retain the copyright to their works, granting to the journal the right to first publication. To facilitate the reuse and distribution, the articles are published under the Creative Commons Attribution (CC-BY 4.0) license. This license allows third parties to use and share published works, provided they attribute the appropriate credit to the original author and acknowledge the publication in the Braz. J. Pharm. Sci. Intellectual Property and Terms of Use Copyright terms applied to the content published in the journal must be clearly stated and differentiated from the copyright terms applied to the website itself. The views, opinions and concepts expressed by the authors, as well as the references accuracy, are solely their own responsibility. The use of generic names, trade names, and trademarks, among others, in this publication does not imply that such names are exempt from copyright restrictions and applicable regulations. Authors are responsible for obtaining necessary permissions for the reuse of copyrighted materials included in their manuscript. All journal content and articles published, unless otherwise specified, are published under the Creative Commons Attribution (CC-BY 4.0) license. Authors retain the copyright of their works, licensing them under the Creative Commons Attribution (CC-BY) license, which allows articles to be reused and distributed without restriction, as long as the original work is correctly cited. The Brazilian Journal of Pharmaceutical Sciences encourages authors to self-archive accepted manuscripts by posting them on personal blogs, institutional repositories, and academic social media platforms. Authors can also post their papers on personal social media accounts, as long as they include the full citation to the version published on the journal's website. Sponsors The Journal receives financial support from: Programa de Apoio às Publicações Científicas Periódicas da USP and the School of Pharmaceutical Sciences, University of São Paulo (USP). Article Processing Charges (APCs) There are no charges for articles submission, evaluation, and publication. |
Editor-in-chief
|
Co-Editor-in-Chief
|
Section Editors
|
Associated Editors
|
Editorial Advisory Board
|
Editorial Production
|
Technical and Administrative Support: Divisão de Biblioteca e Documentação do Conjunto das Químicas da USP-DBDCQ |
|
Available at https://revistas.usp.br/bjps/InstructionstoAuthors. According to the Journal’s policy, manuscripts will not be accepted for publication for the following reasons: 1. Out of scope The work must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
Immediate rejection criteria: a. Description of analytical methods with no relation to pharmaceutics, biopharmaceutics, or pharmaceutical biotechnology. b. Mere description of compound synthesis, processes, validation, etc. without any pharmaceutical application. c. Manuscripts describing plant extract activity that do not identify qualitative and quantitative chemical markers of the extract. d. Inappropriate promotion of a trademark or a product. e. Regulatory issues with no relation to pharmaceutics, biopharmaceutics, or pharmaceutical biotechnology.
2. Too preliminary A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented. Immediate rejection criteria: a. No proof of concept in either an in vivo or an in vitro evaluation. b. No clear indication of the use of the product or formulation. c. No clear description of the materials & methods used in the pharmaceutical field. d. Use of inadequate or insufficient methods. e. Inappropriate statistical analysis. f. Lack of proper controls. g. Lack of coherent discussion of the results.
3. Lack of novelty The study described in the manuscript must represent a novel approach. Immediate rejection criteria: a. Repetition of previously published data, either partially or entirely. b. Simple variation of parameters of a formulation, processes, synthesis, etc. c. Modification of well-known delivery systems with no novelty and/or benefit. d. Plagiarism (unacknowledged copying of other’s work) and self-plagiarism (re-use of parts of an author’s previously published work without proper citation).
In addition, will not be accepted for publication: a. Studies on human subjects not approved by an accredited Ethics Committee or without written informed consent from the subject or legal guardian. b. Studies on animals not approved by an accredited Ethics and Animal Care Committee. Before preparing your manuscript for submission to the Brazilian Journal of Pharmaceutical Sciences, it is imperative that authors meticulously review and follow the guidelines outlined in the section "Preparation of the Manuscript". This introduction serves to emphasize critical aspects that need to be adhered to facilitate a smooth review and publication process. Ensuring compliance with these guidelines not only streamlines the editorial workflow but also enhances the scientific integrity and dissemination of your research. Here is a brief overview to guide your preparation and submission process: 1. **Language and Originality**: All manuscripts must be submitted in English, and the submission must be original work that has not been published elsewhere nor is it under consideration by another publication. 2. **Authorship Criteria**: Only individuals who have significantly contributed to the research and manuscript preparation should be listed as co-authors. Additionally, authors must participate in the discussion of results and approve the final version of the manuscript. 3. **Submission Requirements**: Alongside the manuscript, authors need to include a signed letter as part of the submission package. Authors are required to perform a plagiarism check using any freely available online software and must submit a certificate along with their manuscript asserting that the text does not contain plagiarism. This step places the initial responsibility on the authors to ensure their work is free of plagiarism before formal review. Failure to include this form will prevent the manuscript from proceeding to the review stage. 4. **Peer Review Process**: Manuscripts that meet the submission guidelines will be subject to a peer review by at least two independent referees. The final decision on the manuscript will be made by the Editor-in-Chief based on the referees' recommendations. 5. **Revision Process**: If revisions are necessary, authors are expected to resubmit the revised manuscript within 60 calendar days, incorporating all suggestions and providing a detailed response to reviewer comments. |
Types of Documents Accepted
|
Brazilian Journal of Pharmaceutical Sciences will publish the following type of manuscript categories: Full-Length Original Paper This is a detailed study reporting original research, including comprehensive data and results. Each manuscript should clearly state its objective or hypothesis; the experimental design and methods used; the essential features of any interventions; the main outcome measures; the main results of the study; and a discussion placing the results in the context of published literature. The manuscript should contain:
Short Communication Short communication is a limited report of significant and original experimental and/or theoretical results that fit within the scope of the Journal. It must be of sufficient importance and general interest to justify publication. The manuscript should contain:
Review Article A review article should provide a synthetic and critical analysis of a relevant area and should not be merely a chronological description of the literature. A review article by investigators who have made substantial contributions to a specific area of Pharmaceutical Sciences will be published by invitation by the Editors. However, a letter of intention altogether with an outline of a review article may be submitted to the Editors without prior consultation. If it is judged appropriate for the Journal, the author(s) will be invited to prepare the article for peer review. The manuscript should contain:
Mini review Article A mini review is focused on a restricted part of a subject normally covered in a review article. The structure of the mini review follows the same rules as the review.
Concepts and Comments The Concepts and Comments section provides a platform for readers to present ideas, theories and views. The manuscript should contain:
|
PREPARING YOUR MANUSCRIPT
|
Cover Letter It is important that you include a cover letter with your manuscript. Take time to consider why this manuscript is suitable for publication in the Brazilian Journal of Pharmaceutical Sciences, why will your paper inspire other members of the field, and how will it drive research forward. Please explain these points in your cover letter. The submission letter must also include the following information:
Authorship requirements Only people who directly contributed to the intellectual content of the paper should be listed as authors. Manuscripts must be submitted electronically only. Confirmation of submission will be sent by email to all authors, for their agreement. Authors should meet all following criteria, thereby taking public responsibility for the content of the paper:
The Brazilian Journal of Pharmaceutical Sciences adopts the CRediT (Contributor Roles Taxonomy) taxonomy to accurately identify the contributions of each author in publications. This helps us to assign proper credit to each of the authors with transparency. For more information about the CRediT system, visit the official website: https://credit.niso.org/. Before the references, a topic should be included indicating the contribution of each author to the research. |
Article Submission Format
|
ORGANIZATION OF THE MANUSCRIPT
|
Continuous page numbers are required for all pages including figures. There are no specific length restrictions for the overall manuscript or individual sections. However, we request authors to present and discuss their findings concisely. We recognize that some articles will not be best presented in the suggested research article format. If you have a manuscript that would benefit from a different format, please contact the editors for further discussion. Preferably, manuscripts should be organized into the following sections:
TITLE PAGE Title The title should be as short and informative as possible, should not contain non-standard acronyms or abbreviations, and should not exceed two printed lines. The title should be centered and written in bold as the example below: FREEZE-DRYING OF AMPICILLIN SOLID LIPID NANOPARTICLES USING MANNITOL AS CRYOPROTECTANT Running title This short title, to be used as a page heading, should not exceed 60 characters. Authors and Affiliations Full name (matched with superscript numbers identifying affiliation) must be written in bold and centered. Institution(s) (Department, Faculty/School, University, City, State, Country) of each author (in English) must be centered and written in italic.
Example: 1College of Pharmacy, Anhui University of Chinese Medicine, Hefei, People’s Republic of China, 2School of Life Science, University of Science and Technology of China, Hefei, People’s Republic of China, 3Zhaoke (Hefei) Pharmaceutical Co. Ltd., Hefei, People’s Republic of China Corresponding author One of the authors should be designated as the corresponding author. It is the corresponding author ́s responsibility to ensure that the author list is accurate and complete. If the article has been submitted on behalf of a consortium, all consortium members and affiliations should be listed in the Acknowledgments section. Provide the name, full address, email address, and ORCID number of the author to whom correspondence should be sent, identified with an asterisk. Abstract Since abstracts are published separately by Information Services, they should contain sufficient hard data to be appreciated by the reader. The abstract should not exceed 200 words (250 for reviews) and should be prepared in a single paragraph without topic divisions and margins. The abstract should briefly and clearly present the objective, experimental approach, new results as quantitative data if possible, and conclusions. It should mention the techniques used without going into methodological detail and mention the most important results. Abbreviations should be kept to a minimum and should be defined in both the Abstract and text. Please do not include any reference citations in the abstract. If the use of a reference is unavoidable, the full citation should be given within the abstract. Keywords A list of keywords or indexing terms (no more than 6) should be included avoiding generic terms. Keywords must be separated by dots with only the first letter of the first word in upper case. Example: Apoptosis pharmacokinetics. Toxicology. INTRODUCTION The Introduction should put the focus of the manuscript into a broader context and reflects the present state-of-art of the subject. This should state briefly and clearly the objectives of the investigation with reference to previous works. The introduction should justify the hypothesis of the study. An extensive review of the literature should be avoided and when possible, replaced by recent reviews of the subject. MATERIAL AND METHODS These should be described in sufficient detail that the work can be reproduced. Well-established procedures and techniques require only citation of the original source, except when they are substantially modified. Reports of experimental studies on humans and animals must certify (including the number of protocols) that the research received prior approval by the appropriate institutional review Ethics Committee. RESULTS Results must be presented clearly and concisely and in a logical order. This section should provide the results of all the experiments required to support the conclusions of the paper. When possible, use figures or tables to present data rather than text. Large datasets, including raw data, should be submitted as supplementary files; these are published online and linked to the article. DISCUSSION Discussion should interpret the results and assess their significance in relation to existing knowledge. Speculation not warranted by actual data should be avoided. The Discussion should spell out the major conclusions and interpretations of the work including some explanation of the significance of these conclusions. ACKNOWLEDGMENTS When appropriate, briefly acknowledge technical assistance, advice, and contributions from colleagues. People who contributed to the work but do not fit the criteria for authors should be listed in the Acknowledgments section, along with their contributions. Donations of animals, cells, or reagents should also be acknowledged. Authors must ensure that anyone named in the Acknowledgments agrees to being so named. Financial support for the research and fellowships should be acknowledged in this section (agency and grant number). FIGURES Figures must be submitted in high-resolution (at least 300 dpi). They must be uploaded separately from the manuscript file. The following file formats are accepted: TIFF or JPEG. Preparing figure files for submission The use of figures is mandatory for original articles since it increases the clarity of data. The use of color figures is free of charge. The following guidelines must be observed when preparing figures. Failure to do so is likely to delay the acceptance and publication of the article.
Please note that it is the authors’ responsibility to obtain permission from the copyright holder to reproduce figures (or tables) previously published elsewhere, taking in consideration it will be published as open access. Permission should be indicated in the figure legend, and the original source included in the reference list. TABLES
CITATIONS Citations should be prepared according to Vancouver's standard reference style (https://library.viu.ca/citing/vancouver). They consist of numbers formatted in superscript and placed after the end of the sentence. If the citation includes more than one reference, separate the numbers with a comma or include a range by separating the first and last numbers with a hyphen. Examples: Reference one1. References two and thirteen2,13. References five through seven5-7. REFERENCES References should formatted in the Vancouver style (see the examples below). They should be numbered according to the order in which they appear in the text. The accuracy and completeness of reference data is the responsibility of the authors. Only published references or accepted in the publication phase should be included in the reference list. Meeting abstracts, conference talks, or papers that have been submitted but not yet accepted should not be cited. Limited citation of unpublished work should be included in the body of the text only. All personal communications should be supported by a letter from the relevant authors. Published Papers: All authors should be included in reference lists. Authors (Surname and first name’s initial). Title (Only the first letter in upper case). Journal abbreviation with dot only on the last word. Year;Volume(issue number):first page-last page. Ali A, Iqbal F, Taj A, Iqbal Z, Amin MJ, Iqbal QZ. Prevalence of microvascular complications in newly diagnosed patients with Type 2 diabetes. Pak J Med Sci. 2013;29(4):899-902. Calvo A, Gimenez MJ. Ex Vivo Serum Activity (Killing Rates) After Gemifloxacin 320 mg Versus Trovafloxacin 200 mg Single Doses Against Ciprofloxacin-Susceptible and -Resistant Streptococcus pneumonia. Int J Antimicr Ag. 2007;20:144-6. Article accepted for publication but not yet published: Authors. Title. Journal (abbreviation in normal font), Year of expected publication (in press) at the end of the citation. Janiszewski M, Lopes LR, Carmo AO, Pedro MA, Brandes RP, Santos CXC, Laurindo FR. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J Biol Chem. 2005 (in press). Internet Communication: Ensure that URLs are active and available. Provide DOI, if available. Brazil. Ministério da Saúde, Secretaria de Vigilância em Saúde. Leishmaniose visceral grave: normas e condutas [Internet]. Brasília (DF): Ministério da Saúde, 2006. [citado 2008 Jan 7]. 60 p. (Série A. Normas e Manuais Técnicos). Disponível em: http://dtr2001.saude.gov.br/editora/produtos/livros/ pdf/06_0072_M.pdf CAPES Statistics. [cited 2006 Mar 16]. Available from: http://www.capes.gov.br/capes/portal. Developmental toxicology. [cited 2015 Apr 10]. Available from: http://www.devtox.org/nomenclature/organ.php. Whole Book: Authors. Book title. Edition. City: Publisher; Year. page. Hewitt W. Microbiological assay for pharmaceutical analysis: a rational approach. Boca Raton: CRC Press; 2003. Jenkins PF. Making sense of the chest x-ray: a hands-on guide. New York: Oxford University Press; 2005. 194 p. Book Chapter: Authors. Chapter Title. Editors. In: Editors Book. Book title. Edition. City, Publisher; Year. Pages of citation. Rojko JL, Hardy WD Jr. Feline leukemia virus and other retroviruses. In: Sherding RG, editor. The cat: diseases and clinical management. New York: Churchill Livingstone; 1989. p. 229-332. Laws: Agência Nacional de Vigilância Sanitária (Brazil). Resolução no. 259, de 20 de setembro de 2002. Regulamento Técnico para Rotulagem de Alimentos Embalados. Diário Oficial da União 23 set 2002; Seção 1. Conference or Symposium Proceedings: Cite papers only from published proceedings. Hejzlar RM, Diogo PA. The use of water quality modelling for optimizing operation of a drinking water reservoir. In: Proceedings of the International Conference Fluid Mechanics and Hydrology. 1999 Jun 23-26; Prague. Prague: Institute of Hydrodynamics AS CR; 1999. p 475-482. Proceedings of the 10th annual meeting of the Canadian Society for Pharmaceutical Sciences. J Pharm Pharm Sci. 2007 Dec 3;10(4):1s-186s. Report Page E, Harmey JM. Health hazard evaluation report. Cincinnati (OH): National Institute for Occupational Safety and Health (US); 2001 Feb. 24p. Report Nº.: HETA2000-0139-2824. Audiovisual Material Physician’s Desk Reference (PDR). Release 2003.1AX. [CD- ROM]. Montvale: Thomson PDR; 2003. Computer Program Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, et al. Epi info, version 6.04: a word processing database and statistics program for public health on IBM- compatible microcomputers. [Computer program]. Atlanta: Centers of Disease Control and Prevention;1998. World Health Organization. WHO. Working to overcome the global impact of neglected tropical diseases, First WHO report on neglected tropical diseases. Geneva, Switzerland: WHO Press; 2010. Patent Larsen CE, Trip R, Johnson CR. Methods for procedures related to the electrophysiology of the heart. Patent No.5.529.067. Novoste Corporation; 1995. Thesis and Dissertations Joselevitch C. Visão no ultravioleta em Carassius auratus (Ostariophysi, Cypriformes, Cyprinidae): estudo eletrofisiológico do sistema cone - células horizontais. [dissertação]. São Paulo: Instituto de Psicologia, USP; 1999. Hernandez CD. Pharmacogenomic analysis in patients with familial hypercholesterolemia [master´s thesis]. São Paulo, Faculdade de Ciências Farmacêuticas, USP; 2021. Unpublished results and Personal communication: Reference should appear in the text with the individual name(s) and initials and not in the reference list. (Santos CS, da-Silva GB, Martins LT, unpublished results). It is assumed that the author has obtained permission from the source when personal communication is cited. Complementary Information This journal follows the principles of transparency and good practices in academic publications established by COPE, available in: https://publicationethics.org |
HOW TO SUBMIT THE MANUSCRIPT
|
Submissions should be sent electronically through the ScholarOne system. All submitted manuscripts undergo an initial checklist. Submissions will be rejected if they do not contain the following: -A signed letter agreeing to the submission with all the necessary statements and information; -Citations and references formatted according to the Vancouver style; -If the manuscript contains figures, they should be submitted separately, in JPEG or TIFF format, with resolution of at least 300 DPI; Make sure to follow closely the instructions detailed in the “PREPARING YOUR MANUSCRIPT” section. If you need further assistance, please contact the Journal Staff (bjps@usp.br). |
|
Additional information:
Brazilian Journal of Pharmaceutical Sciences |
Read our Open Access Statement